Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines EPS (earnings per share) 2017–2026What is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
Revolution Medicines's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was -1.90 USD, against a loss of 1.61 USD on the same quarter a year before. Revolution Medicines's diluted earnings per share in fiscal year 2025 were -5.95 USD, against a loss of 3.58 USD on the year before.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
EPS
| Fiscal year | Period ending | EPS | Growth | EPS (basic) |
|---|---|---|---|---|
| TTM | 30 Sept 2026 | -9.15 | — | -9.15 |
| FY2025 | 31 Dec 2025 | -5.95 | — | -5.95 |
| FY2024 | 31 Dec 2024 | -3.58 | — | -3.58 |
| FY2023 | 31 Dec 2023 | -3.86 | — | -3.86 |
| FY2022 | 31 Dec 2022 | -3.08 | — | -3.08 |
| FY2021 | 31 Dec 2021 | -2.57 | — | -2.47 |
| FY2020 | 31 Dec 2020 | -1.62 | — | -1.62 |
| FY2019 | 31 Dec 2019 | -1.31 | — | -1.31 |
| FY2018 | 31 Dec 2018 | -1.15 | — | -1.15 |
| FY2017 | 31 Dec 2017 | -0.85 | — | -0.85 |
| Quarter | Period ending | EPS | Growth on a year before | EPS (basic) |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | -1.90 | — | -1.90 |
| Q2 FY2026 | 30 Jun 2026 | -3.06 | — | -3.06 |
| Q1 FY2026 | 31 Mar 2026 | -2.29 | — | -2.29 |
| Q4 FY2025 | 31 Dec 2025 | -1.90 | — | -1.90 |
| Q3 FY2025 | 30 Sept 2025 | -1.61 | — | -1.61 |
| Q2 FY2025 | 30 Jun 2025 | -1.31 | — | -1.31 |
| Q1 FY2025 | 31 Mar 2025 | -1.13 | — | -1.13 |
| Q4 FY2024 | 31 Dec 2024 | -1.13 | — | -1.13 |
| Q3 FY2024 | 30 Sept 2024 | -0.94 | — | -0.94 |
| Q2 FY2024 | 30 Jun 2024 | -0.81 | — | -0.81 |
| Q1 FY2024 | 31 Mar 2024 | -0.70 | — | -0.70 |
| Q4 FY2023 | 31 Dec 2023 | -1.14 | — | -1.14 |
| Q3 FY2023 | 30 Sept 2023 | -0.99 | — | -0.99 |
| Q2 FY2023 | 30 Jun 2023 | -0.92 | — | -0.92 |
| Q1 FY2023 | 31 Mar 2023 | -0.72 | — | -0.62 |
| Q4 FY2022 | 31 Dec 2022 | -0.63 | — | -0.63 |
| Q3 FY2022 | 30 Sept 2022 | -0.87 | — | -0.87 |
| Q2 FY2022 | 30 Jun 2022 | -0.81 | — | -0.81 |
| Q1 FY2022 | 31 Mar 2022 | -0.77 | — | -0.77 |
| Q4 FY2021 | 31 Dec 2021 | -0.71 | — | -0.71 |
| Q3 FY2021 | 30 Sept 2021 | -0.72 | — | -0.72 |
| Q2 FY2021 | 30 Jun 2021 | -0.60 | — | -0.60 |
| Q1 FY2021 | 31 Mar 2021 | -0.53 | — | -0.53 |
| Q4 FY2020 | 31 Dec 2020 | -0.52 | — | -0.52 |
| Q3 FY2020 | 30 Sept 2020 | -0.42 | — | -0.42 |
| Q2 FY2020 | 30 Jun 2020 | -0.46 | — | -0.46 |
| Q1 FY2020 | 31 Mar 2020 | -0.67 | — | -0.67 |
| Q4 FY2019 | 31 Dec 2019 | -0.40 | — | -0.40 |
| Q3 FY2019 | 30 Sept 2019 | -0.35 | — | -0.35 |
| Q2 FY2019 | 30 Jun 2019 | -0.28 | — | -0.28 |
| Q1 FY2019 | 31 Mar 2019 | -0.28 | — | -0.28 |
| Q4 FY2018 | 31 Dec 2018 | -0.31 | — | -0.31 |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Income statement
Common questions about Revolution Medicines's EPS
Source: Financial Modeling PrepVerified against SEC filings